Tag:

Productos Sanitarios

Health

EU Designates Reference Labs for In Vitro Diagnostic Devices – Spain Included

by Chief Editor
written by Chief Editor

EU Bolsters Diagnostic Testing Infrastructure: What It Means for the Future of Infection and Blood Grouping Analysis

The European Commission has recently designated key Reference Laboratories (EURLs) for in vitro diagnostic medical devices (IVDs) focused on parasitic infection markers and blood grouping. This move, detailed in Regulation (EU) 2025/2526, isn’t just a bureaucratic update; it signals a significant investment in the accuracy, reliability, and future of diagnostic testing across Europe. Spain’s Instituto de Salud Carlos III and Consulting Químico Sanitario SLU have been selected, alongside facilities in Germany and Sweden, to play a pivotal role.

The Rising Importance of Accurate Diagnostics

The demand for precise and rapid diagnostic testing is surging globally. Driven by factors like an aging population, increasing prevalence of chronic diseases, and the ever-present threat of emerging infectious diseases – as vividly demonstrated by the COVID-19 pandemic – the need for robust diagnostic infrastructure has never been greater. According to a report by Grand View Research, the global in vitro diagnostics market was valued at USD 79.81 billion in 2023 and is projected to reach USD 128.38 billion by 2030, growing at a CAGR of 6.9%.

This growth isn’t uniform. Diagnostics for parasitic infections, particularly in regions with limited resources, remain a critical need. Similarly, advancements in blood grouping technologies are essential for safe and efficient blood transfusions, especially with the increasing complexity of patient needs and the rise of rare blood types.

What Do EURLs Actually Do?

These aren’t just testing centers. EURLs act as central hubs for scientific and technical assistance, ensuring consistency and comparability of results across different laboratories and member states. They’ll be involved in evaluating high-risk diagnostic tests (Class D) and providing expert advice. Specifically, they will verify the performance claimed by manufacturers and analyze sample batches to ensure quality control. This is particularly crucial for IVDs, where even minor inaccuracies can have serious consequences for patient care.

Pro Tip: Understanding the classification of IVDs (A, B, C, and D) is key. Class D devices, representing the highest risk, require the most stringent evaluation and oversight, making the EURL’s role paramount.

Future Trends: Beyond Traditional Testing

The designation of these EURLs isn’t a static event; it’s a stepping stone towards several exciting developments in diagnostic testing:

  • Point-of-Care Diagnostics (POCT): We’ll see a continued push for rapid, decentralized testing that can be performed near the patient – in doctors’ offices, pharmacies, or even at home. EURLs will play a role in validating the accuracy and reliability of these increasingly sophisticated POCT devices.
  • Multiplex Testing: The ability to detect multiple pathogens or biomarkers simultaneously is becoming increasingly important. EURLs will be instrumental in establishing standardized protocols and quality control measures for these complex assays.
  • Artificial Intelligence (AI) and Machine Learning (ML): AI and ML are revolutionizing diagnostics, enabling faster and more accurate analysis of complex data. EURLs will need to adapt to evaluate and validate AI-powered diagnostic tools.
  • Next-Generation Sequencing (NGS): NGS is transforming infectious disease diagnostics, allowing for rapid identification of pathogens and detection of antimicrobial resistance. EURLs will be vital in ensuring the accuracy and reliability of NGS-based tests.
  • Personalized Medicine: Diagnostics are becoming increasingly tailored to individual patients, taking into account their genetic makeup and other factors. EURLs will contribute to the development and validation of personalized diagnostic tests.

The Spanish Contribution: A Hub for Innovation

The selection of the Instituto de Salud Carlos III and Consulting Químico Sanitario SLU highlights Spain’s growing expertise in diagnostic testing. The Agencia Española de Medicamentos y Productos Sanitarios (Aemps) played a key role in submitting successful applications, demonstrating a commitment to strengthening the country’s diagnostic capabilities. This positions Spain as a potential leader in the development and implementation of innovative diagnostic solutions.

Did you know? The Aemps launched a second call for EURL designations for IVDR in March 2025, indicating a proactive approach to expanding Spain’s role in European diagnostic testing.

Implications for Manufacturers and Healthcare Providers

Manufacturers of Class D IVDs will now be required to submit their products for verification and batch analysis by the designated EURLs, starting May 1, 2026, for formal evaluations. This will likely lead to increased scrutiny and a higher bar for product approval. Healthcare providers can expect more reliable and standardized test results, ultimately leading to improved patient care.

FAQ

Q: What is an EURL?
A: An EURL (European Union Reference Laboratory) is a designated laboratory responsible for providing scientific and technical assistance, evaluating high-risk diagnostic tests, and ensuring consistency across member states.

Q: When will the new regulations be fully implemented?
A: The regulations are in effect now, but specific tasks related to scientific and technical assistance begin May 1, 2026. Verification of manufacturer-declared performance applies to submissions from May 1, 2026, onwards.

Q: What does this mean for patients?
A: Ultimately, this means more accurate and reliable diagnostic testing, leading to better diagnoses and more effective treatment.

Q: Where can I find more information about the regulations?
A: You can find the full text of Regulation (EU) 2025/2526 on the EUR-Lex website.

Want to learn more about the latest advancements in diagnostic testing? Explore our other articles on medical technology or subscribe to our newsletter for regular updates.

0 comments
0 FacebookTwitterPinterestEmail
Health

Aemps se une como coevaluador en la evaluación clínica europea

by Chief Editor
written by Chief Editor

Europe’s Health‑Technology Assessment Landscape Is Shifting – What It Means for Patients and Pharma

From the moment the European HTA Regulation entered into force, member‑state agencies have been racing to harmonise clinical assessments across borders. The Spanish Agency for Medicines and Health Products (AEMPS) has just taken a historic step by joining a Joint Clinical Assessment (JCA) as a co‑evaluator. This move signals three emerging trends that will shape the future of health‑technology assessment (HTA) in Europe.

1️⃣ Greater Cross‑Border Collaboration in Clinical Evidence Review

With twelve JCAs already underway, the EU is creating a single “evaluation pipeline” that reduces duplicated work in each country. By sharing data, methodologies, and timelines, agencies can issue a single, harmonised clinical report that all 27 member states accept.

  • Real‑life example: The ongoing JCA for ensartinib, an ALK‑inhibitor for advanced non‑small‑cell lung cancer (NSCLC), already features input from Spain, France, Italy and the Netherlands. Early coordination of PICOs (Population, Intervention, Comparator, Outcomes) means the final report will reflect the therapeutic realities in each market.
  • Data point: A 2023 EU HTA Survey found that 78 % of national agencies consider JCAs “essential” for speeding up market access.

2️⃣ Patient‑Centred Evidence Generation Becomes the Norm

The new HTA model puts patients at the centre of assessment. AEMPS, for instance, is actively transmitting Spanish patient‑needs into JCA scope definitions. This ensures that outcomes most relevant to patients—such as quality‑of‑life metrics or real‑world adverse‑event data—are weighted alongside traditional efficacy endpoints.

Pro tip: Companies that embed patient‐reported outcome (PRO) measures early in their trial design are now seeing a 15‑20 % faster time‑to‑reimbursement in countries that adopt JCA pathways.

3️⃣ Digital Platforms Will Accelerate Evidence Synthesis

Artificial intelligence‑driven literature‑review tools and interoperable data‑exchange standards are being piloted across the HTA network. By 2027, the EU expects a “single‑source” digital repository where every submitted dossier is instantly searchable by all participating agencies.

According to a 2024 NICE technical report, agencies that used AI‑assisted systematic reviews reduced their assessment time by an average of 30 %.

What These Trends Mean for Stakeholders

For Pharmaceutical Companies

  • Prepare uniform dossiers that meet the pan‑European JCA template.
  • Invest in robust PRO data and real‑world evidence (RWE) from the outset.
  • Adopt AI tools for rapid literature synthesis to stay ahead of evaluation timelines.

For Healthcare Professionals

Clinicians will receive clearer, harmonised guidance on new therapies, reducing confusion caused by divergent national recommendations. This enables faster adoption of breakthrough treatments like ensartinib for ALK‑positive NSCLC.

For Patients

Faster, consistent approvals translate into earlier access to innovative medicines, while patient‑centric outcome measures ensure that approved treatments truly address everyday needs.

Frequently Asked Questions

What is a Joint Clinical Assessment (JCA)?

A JCA is a collaborative clinical evaluation conducted by multiple EU HTA bodies, resulting in a single evidence report that all participating countries can use for reimbursement decisions.

How does AEMPS’s role as a co‑evaluator influence the assessment?

As a co‑evaluator, AEMPS contributes scientific expertise, ensures Spanish patient perspectives are considered, and helps harmonise the final report with national health‑system priorities.

Will JCAs replace national HTA processes?

Not entirely. JCAs provide the clinical evidence component, but each country may still conduct its own economic and budget impact analysis before final reimbursement.

How can companies prepare for the JCA process?

Submit dossiers that align with the European HTA template, integrate high‑quality PRO and RWE data, and engage early with national agencies to shape the PICOs.

What’s Next?

The EU’s HTA ecosystem is still evolving. Expect the number of JCAs to double by 2028, with more therapeutic areas—such as rare diseases and advanced therapies—joining the collaborative fold. Keeping an eye on the evolving guidelines published by the European Medicines Agency (EMA) will be crucial for staying ahead.

Stay informed! Subscribe to our newsletter for the latest updates on European HTA, upcoming JCAs, and actionable strategies for market access. Join now and never miss a beat.

Explore more on our site:

0 comments
0 FacebookTwitterPinterestEmail
Health

Aemps & CEIm to Collaborate on IVD Medical Device Evaluation

by Chief Editor
written by Chief Editor

Navigating the Future of Clinical Research and Medical Devices: Trends and Insights

As a healthcare journalist, I’ve spent years covering the evolving landscape of clinical research and medical devices. Recent developments, particularly from regulatory bodies like the Spanish Agency of Medicines and Medical Devices (AEMPS), highlight a critical need for harmonization and clarity in how we approach clinical trials and studies involving medical devices. This article explores these trends, offering insights into the future of medical innovation and patient safety.

Harmonization of Standards: A Global Imperative

The AEMPS memorandum, which outlines the collaboration between the agency and the Research Ethics Committees (CEIm), is a crucial step. This mirrors a global push for standardization, ensuring that clinical trials, regardless of location, adhere to consistent ethical and regulatory frameworks. The goal? To streamline processes, reduce discrepancies, and ultimately, accelerate the development of life-saving medical advancements.

Did you know? The harmonization of clinical trial regulations is not just a European effort. Organizations like the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) work to align guidelines worldwide, promoting consistent quality, safety, and efficacy in drug development.

Digital Transformation in Clinical Trials

One of the most significant trends is the adoption of digital technologies. Remote patient monitoring, telemedicine, and electronic data capture (EDC) are reshaping the way clinical trials are conducted. These tools enhance efficiency, reduce costs, and improve patient access, especially for those in remote areas or with mobility limitations. Expect to see a surge in the use of AI for data analysis and personalized medicine, too.

Pro Tip: Keep an eye on the development of decentralized clinical trials (DCTs). These trials are conducted remotely, offering patients greater convenience and expanding the pool of potential participants.

Focus on In Vitro Diagnostics (IVDs): The Diagnostic Revolution

The AEMPS memorandum’s inclusion of in vitro diagnostic (IVD) devices underscores the growing importance of diagnostics. IVDs are critical for early disease detection, treatment monitoring, and personalized medicine. The regulatory framework, still under development in some regions, aims to provide clear guidance for evaluating the performance and safety of these devices. The trend is toward more sophisticated, rapid, and accessible diagnostic tools, driven by advances in areas like molecular diagnostics and point-of-care testing.

Consider the rise of liquid biopsies for cancer detection. These tests analyze blood samples to identify cancer cells or DNA fragments, offering a less invasive and potentially earlier detection method compared to traditional biopsies. The future of diagnostics lies in creating better tools for better treatments. This is also opening up the door for earlier trials, more accessible treatments, and much-needed improvements in patient quality of life.

Ethical Considerations and Patient Safety

As innovation accelerates, ethical considerations remain paramount. The CEIm plays a vital role in ensuring patient safety and upholding ethical standards in research. This includes reviewing informed consent procedures, data privacy, and the overall welfare of study participants. The focus is on transparency, patient empowerment, and building trust in clinical research.

Example: The use of wearable devices in clinical trials raises privacy concerns. Researchers must ensure the secure handling of patient data and obtain explicit consent for its use.

The Regulatory Landscape: Adapting to Innovation

Regulatory bodies are constantly adapting to the fast pace of medical innovation. The AEMPS’s role in authorizing clinical investigations reflects a broader trend of regulators working collaboratively with stakeholders. This helps to create a flexible and responsive regulatory landscape. This iterative approach is essential to support innovation while protecting patient safety. Expect to see more emphasis on risk-based approaches and adaptive pathways, allowing faster access to promising medical technologies.

For more information, see the AEMPS website.

The Future is Collaborative

The path forward is undoubtedly collaborative. Successful clinical research and medical device development will require a cohesive effort from regulatory bodies, research ethics committees, sponsors, researchers, healthcare providers, and patients. The focus will be on transparency, data sharing, and continuous learning to improve patient outcomes. Harmonization is the key, with increased focus on international collaboration and shared resources.

Are you interested in learning more about specific areas of clinical research or medical device development? Do you have any questions about the regulatory process? Share your thoughts in the comments below!

0 comments
0 FacebookTwitterPinterestEmail
World

China Responds to EU Restrictions: Healthcare Import Measures

by Chief Editor
written by Chief Editor

China-EU Trade Tensions: A Glimpse into the Future of Global Healthcare and Commerce

The recent tit-for-tat trade restrictions between China and the European Union, particularly regarding healthcare products, signal a potential reshaping of global commerce. This isn’t just a spat over tariffs; it’s a clash of ideologies about market access and the future of economic partnerships. Understanding the underlying dynamics is crucial for businesses and policymakers alike.

The Spark: Healthcare and Reciprocity

The initial trigger was the EU’s decision to restrict Chinese companies from bidding on public healthcare contracts, citing a lack of reciprocal market access in China. This move, backed by the International Procurement Instrument, aimed to ensure fair play. In response, China has now announced its own restrictions on the purchase of EU healthcare products, escalating the tension.

Did you know? The EU’s International Procurement Instrument, or IPI, is a relatively new tool designed to address imbalances in access to public procurement markets. Learn more about the IPI here.

The Broader Context: A New World Order?

These actions are not isolated incidents. They reflect a broader trend of rising protectionism and geopolitical friction. Trade disputes between major economic blocs, such as the US-China trade war, have set a precedent. The EU and China are major players on the world stage and their relationship will impact on how global trade is conducted in the coming years.

The recent actions also come at a time when the EU and China are facing other friction points: the EU’s recently announced tariffs on Chinese-made electric vehicles, and China’s retaliatory tariffs on brandy. This suggests a deeper strategic realignment is in progress. China is working hard to become more self-sufficient by reducing its reliance on imports.

Future Trends and Potential Impacts

So, what does this mean for the future? Here are a few potential trends to watch:

  • Diversification of Supply Chains: Businesses will likely seek to diversify their supply chains to mitigate risks associated with geopolitical uncertainties. This means sourcing healthcare products (and other goods) from a wider range of countries, reducing reliance on any single market.
  • Rise of Regional Trade Blocs: We could see a stronger emphasis on regional trade agreements. The EU might strengthen ties with other like-minded nations, while China could focus on partnerships in Asia and Africa.
  • Focus on Domestic Production: Governments may prioritize domestic production of essential goods, including pharmaceuticals and medical devices, to bolster national security and reduce dependence on imports.
  • Increased Scrutiny of Foreign Investment: Foreign investment in strategic sectors, like healthcare, will likely face increased scrutiny. Governments might impose stricter regulations to protect domestic industries and ensure fair competition.

Impact on Healthcare Businesses

Healthcare companies, especially those operating in both the EU and China, face significant challenges. They must navigate complex regulations, manage fluctuating trade costs, and adapt to shifting market dynamics. Successful companies will need to:

  • Develop robust risk management strategies: Assess their exposure to trade-related risks and diversify their supply chains accordingly.
  • Build strong government relations: Engage with policymakers to advocate for their interests and stay informed about evolving trade policies.
  • Embrace innovation and flexibility: Adapt their business models to capitalize on emerging opportunities and navigate regulatory hurdles.

The Role of Technology

Technology plays a critical role. The companies that excel will take advantage of digital platforms and technologies. The companies that can use data analytics and AI to create more efficient supply chains will stay ahead of the game. This includes the use of advanced analytics and data. Blockchain could be useful for improved transparency and security, especially within supply chains.

Pro Tip: Stay informed by subscribing to industry newsletters and attending trade conferences to keep abreast of the latest developments in international trade and healthcare regulations.

FAQ: Your Questions Answered

What are the main products affected by the trade restrictions?

Primarily healthcare products, including medical devices, pharmaceuticals, and other medical supplies, are affected.

How will these restrictions impact consumers?

Consumers may face higher prices and limited access to certain products as a result of increased costs and supply chain disruptions.

Are there any potential benefits to these trade restrictions?

They may encourage domestic innovation and production, potentially creating jobs and strengthening local industries. They may also make supply chains more resilient to external shocks.

If you want to learn more, please check out our other articles about trade or sign up for our newsletter. What are your thoughts on this changing landscape of global trade? Share your thoughts in the comments below!

0 comments
0 FacebookTwitterPinterestEmail
Health

El Supremo Analizará la Confidencialidad de los Contratos de Vacunas COVID-19: Implicaciones y Opiniones

by Chief Editor
written by Chief Editor

The Supreme Court’s Role in Setting Transparency Standards for Vaccine Procurement

The Supreme Court of Spain recently admitted a key appeals case challenging the transparency of vaccine procurement agreements against COVID-19. This follows a government refusal to disclose details of contracts, including pricing and terms, with pharmaceutical companies and international bodies.

Taken to court by the Council of Transparency and Good Governance, the case questions the legitimacy of applying confidentiality clauses to prevent public access to key contract details. The council argues that transparency needs balancing with the public’s right to be informed of these agreements.

The Origins of the Legal Dispute

This legal battle originates from a June 2024 ruling by the National Court, which supported the Spanish Agency for Medicines and Health Products (AEMPS). The court held that releasing certain information, like pricing and negotiation terms, could undermine the European Commission’s bargaining power in future drug and vaccine bulk purchases.

The refusal to disclose information was justified by EU Union jurisprudence, which recognizes the sensitive nature of these agreements. EU regulations allow exceptions for information access if disclosure could weaken manufacturer competition or diplomatic ties.

Transparency vs. Confidentiality on the Global Stage

The Supreme Court must determine whether confidentiality clauses from the Regulation 1049/2001 of the EU Parliament apply to Spain’s vaccine purchase agreements. Additionally, it will consider if foreign relations protection can justify withholding document access.

A decision by the TS might influence global practices, as similar transparency cases have arisen in other EU countries regarding vaccine contracts. The European Ombudsman previously urged for greater transparency, although some published documents remain heavily redacted.

How the Supreme Court’s Verdict May Reshape Policies

The Supreme Court’s forthcoming ruling could set a precedent defining transparency levels in international healthcare purchases. Should the court favor public disclosure, the government may be compelled to reveal until-now confidential contract details. Conversely, upholding current confidentiality practices could solidify restrictive transparency standards.

Future Trends in Vaccine Procurement Transparency

As pandemic management continues to rely on international agreements, the Supreme Court’s decision may influence the degree of information accessibility citizens can demand regarding state-financed medical procurement. The ruling could serve as a blueprint for balancing transparency with strategic confidentiality in future health crises.

Frequently Asked Questions (FAQ)

Why is vaccine procurement transparency important?

Transparency ensures public trust and accountability, allowing citizens to understand how resources are allocated during health crises and enabling informed public discourse.

How could greater transparency impact national security?

While openness can lead to competitive disadvantages, robust transparency with careful redaction can protect sensitive information while fostering trust.

Did you know? The European Ombudsman’s push for transparency emphasizes the growing global call for balancing state security with public information rights.

In-Depth Analysis and Insights

Similar transparency debates have unfolded in the United States and Canada over contracts with Pfizer, Moderna, and AstraZeneca. Here, the tension lies between the public’s right to information and the need to preserve future crisis negotiation capabilities. Analyses from these cases can offer valuable insights into possible outcomes of the Spanish Supreme Court ruling.

Engage with the Future of Transparency

As this landmark case unfolds, it’s crucial to stay informed. What are your thoughts on balancing transparency with confidentiality in public contracts? Share your insights in the comments or subscribe to our newsletter for updates on this evolving story.

This content is structured to be seamlessly incorporated into WordPress as a post, engaging readers with a comprehensive view on the potential impact of the Supreme Court ruling on transparency in vaccine procurement. It maintains a professional yet conversational tone that encourages active reader participation and further exploration of the topic.

0 comments
0 FacebookTwitterPinterestEmail